CKD CKD
Conditions
Interventions
Single-dose administration of dantrolene 25 mg
Sponsors
Uchinoumi Hitoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Chronic Kidney Disease (CKD) 2) Estimated glomerular filtration rate (eGFR): 25-45 mL/min/1.73m2 3) Age >= 20 years old 4) Male and female 5) Inpatient of Yamaguchi university hospital 6) No acute renal failure, acute decompensated heart failure, or lethal arrythmia 7) Written consent to participate in the study from the individual
Exclusion criteria
Exclusion criteria: 1) Patients receiving therapy with immune suppressive drugs (e.g. prednisolone >=5 mg/day or equivalent), who primary investigator and investigators consider as unstable condition of the disease. 2) Use of potassium adsorbents within 2 months prior to enrollment 3) Patients with drug-induced renal dysfunction 4) Patients who continuously receive hemodialysis and peritoneal dialysis or are planned to receive these renal replacement therapy 5) History of renal transplantation, or is planned to receive this surgery after enrollment 6) Uncontrollable Diabetes mellitus, hypertension or hyperthyroidism 7) Patients with COPD and severe respiratory dysfunction 8) Patients diagnosed with myasthenia gravis 9) Patients with severe liver dysfunction 10) Patients with ileus 11) Patients who could not receive oral medication 12) History of allergy and hypersensitivity for dantrolene 13) Pregnant or potentially pregnant women or breastfeeding 14) Patients with severe inflammatory disease such as sepsis and pneumonia etc. 15) Patients with active cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety (Adverse events) | — |
Contacts
Public ContactHitoshi Uchinoumi
Yamaguchi University
Outcome results
None listed